Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic,programmed death-ligand 1-positive,non-small-cell lung cancer
Restricted accessCase reportFirst published online August, 2021
Acute cytokine release syndrome after a first dose of pembrolizumab as second-line treatment for metastatic,programmed death-ligand 1-positive,non-small-cell lung cancer
The use of programmed death-ligand 1 (PD-L1) checkpoint inhibitor therapy is expanding, although its adverse effects are not completely known. We report on a rare case of acute cytokine release syndrome related to pembrolizumab use in a patient with lung cancer.
Case report
A 79-year-old man with metastatic, PD-L1-positive, non-small-cell lung cancer developed a febrile condition associated with a systemic inflammatory response syndrome and suffered haemodynamic compromise four hours after the first intravenous administration of pembrolizumab. A thorough medical workup found no alternative cause and a grade 2 cytokine release syndrome (CRS) was diagnosed.
Management and outcome: Aggressive fluid resuscitation and supportive therapy led to restitutio ad integrum.
Discussion
Acute CRS after the administration of a PD-L1 inhibitor is infrequent but could be a fatal condition. Supportive treatment and, if necessary, corticosteroids should be considered.
World Health Organisation-The global cancer observatory, https://gco.iarc.fr/today. (accessed 1 November 2019).
2.
GrosARobbinsPFYaoX, et al.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest2014;
124: 2246–2259.
3.
AhmadzadehMJohnsonLAHeemskerkB, et al.
Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood2009;
114: 1537–1544.
4.
SchoenhalsJESeyedinSNAndersonC, et al.
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res2017;
6: 148–158.
5.
KonishiJYamazakiKAzumaM, et al.
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res2004;
10: 5094–5100.
6.
ButteMJKeirMEPhamduyTB, et al.
Programmed death-L1 interacts specifically with B7-1 costimulary molecule to inhibit T cell responses. Immunity2007;
27: 111–122.
7.
FranciscoLMSalinasVHBrownKE, et al.
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med2009;
206: 3015–3029.
8.
PatsoukisNBrownJPetkovaV, et al.
Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal2012;
5: ra46.
9.
BrahmerJRPardollDM.Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res2013;
1: 85–91.
10.
PlanchardDPopatSKerrK, et al.; ESMO Guidelines Committee.Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol2018;
29: iv192–iv237.
11.
OdaHIshiharaMMiyaharaY, et al.
First case of cytokine release syndrome after nivolumab for gastric cancer. Case Rep Oncol2019;
12: 147–156.
12.
KogureYIshiiYOkiM.Cytokine release syndrome with pseudoprogression in a patient with advanced non-small cell lung cancer treated with pembrolizumab. J Thorac Oncol2019;
14: e55–e57.
13.
NaranjoCABustoUSellersEM, et al.
A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;
30: 239–245.
14.
NosakiKSakaHHosomiY, et al.
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer2019;
135: 188–195.
LeeDWGardnerRPorterDL, et al.
Current concepts in the diagnosis and management of cytokine release syndrome. Blood2014;
124: 188–195.
17.
FerrariSMFallahiPEliaG, et al.
Autoimmune endocrine dysfunctions associated with cancer immunotherapies. IJMS2019;
20: 2560.
18.
MokTSKWuYLKudabaI, et al.; KEYNOTE-042 Investigators.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet2019;
393: 1819–1830.
19.
ShimizuTSetoTHiraiF, et al.
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in japanese patients with advanced solid tumors. Invest New Drugs2016;
34: 347–354.
20.
KhojaLDayDWei-Wu ChenT, et al.
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol2017;
28: 2377–2385.
21.
WangPFChenYSongSY, et al.
Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a Meta-analysis. Front Pharmacol2017;
8: 730.
22.
FajeATSullivanRLawrenceD, et al.
Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab2014;
99: 4078–4085.
23.
Barroso-SousaRBarryWTGarrido-CastroAC, et al.
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and Meta-analysis. JAMA Oncol2018;
4: 173–182.
24.
SinghHKimGMaherVE, et al.
FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol2016; 34(suppl): 10010.
25.
DasteADomblidesCGross-GoupilM, et al.
Immune checkpoint inhibitors and elderly people: a review. Eur J Cancer2017;
82: 155–166.
26.
HerzSHöferTPapapanagiotouM, et al.
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer2016;
67: 66–72.
27.
KanzBAPollackMHJohnpulleR, andal.
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer2016;
4: 60.
28.
DwightHOLaiWErinMB, et al.
Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non–small-cell lung cancer. Clin Lung Cancer2018;
19: e893–e900.
29.
SternscheinRMollMNgJ, et al.
Immune checkpoint inhibitor-related pneumonitis. Incidence, risk factors, and clinical and radiographic features. Am J Respir Crit Care Med2018;
198: 951–953.
30.
KimKWRamaiyaNHKrajewskiKM, et al.
Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs2013;
31: 1071–1077.
31.
SriratanaPNortonJ.New immunotherapies in oncology treatment and their side effect profiles. J Am Board Fam Med2018;
31: 620–627.
32.
WangCThudiumKBHanM, et al.
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res2014;
2: 846–856.
33.
ZhouG-WXiongYChenS, et al.
Anti-PD-1/PD-L1 antibody therapy for pretreated advanced non-small-cell lung cancer. A Meta-analysis of randomized clinical trials. Medicine2016;
95: e4611.
34.
JunSYukihiroTMasatakaT, et al.
Relationship between programmed cell death protein ligand 1 expression and immune-related adverse events in non-small-cell lung cancer patients treated with pembrolizumab. JMA J2020;
3: 58–66.
35.
MurthyHIqbalMChavezJC, et al.
Cytokine release syndrome: current perspectives. Immunotargets Ther2019;
8: 43–52.
VincentJLMorenoRTakalaJ, et al.
The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine. Intensive Care Med1996;
22: 707–710.
38.
RahmatinejadZReihaniHTohidinezhadF, et al.
Predictive performance of the SOFA and mSOFA scoring systems for predicting in-hospital mortality in the emergency department. Am J Emerg Med2019;
37: 1237–1241.
39.
MazzolaPBellelliGPeregoS, et al.
The sequential organ failure assessment score predicts 30-day mortality in a geriatric acute care setting. J Gerontol A Biol Sci Med Sci2013;
68: 1291–1295.
40.
GarberoRFSimõesAAMartinsGA, et al.
SOFA and qSOFA at admission to the emergency department: diagnostic sensitivity and relation with prognosis in patients with suspected infection. Turk J Emerg Med2019;
19: 106–110.
41.
ProbstLSchalkELiebregtsT, et al.; for the Working Party on Intensive Care Medicine in Hematologic and Oncologic Patients (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO).
Prognostic accuracy of SOFA, qSOFA and SIRS criteria in hematological cancer patients: a retrospective multicenter study. J Intensive Care2019;
7: 41.
42.
ChaeBRKimYJLeeYS.Prognostic accuracy of the sequential organ failure assessment (SOFA) and quick SOFA for mortality in cancer patients with sepsis defined by systemic inflammatory response syndrome (SIRS). Support Care Cancer2020;
28: 653–659.
